COSMOS Pharmaceutical (3349) Fundamentals 2026 — P/E 15.3x, Revenue Analysis | SniperIQ
COSMOS Pharmaceutical (3349) is a JP-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥489.9B, trading at ¥6181.00 on the JPX. This SniperIQ fundamentals page covers COSMOS Pharmaceutical's valuation (P/E 15.3x, P/B 1.7x), profitability (net margin 2.9%), revenue (¥1.10T in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is COSMOS Pharmaceutical's market cap?
COSMOS Pharmaceutical (3349) has a market capitalization of approximately ¥489.9B, trading at ¥6181.00 on the JPX. Market cap moves with the live share price.
What is COSMOS Pharmaceutical's P/E ratio?
COSMOS Pharmaceutical's trailing twelve-month P/E ratio is 15.3x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is COSMOS Pharmaceutical?
COSMOS Pharmaceutical runs a net profit margin of 2.9%, a gross margin of 20.9%, and an operating margin of 3.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does COSMOS Pharmaceutical generate?
COSMOS Pharmaceutical reported revenue of ¥1.10T for fiscal year 2026, with net income of ¥32.0B and earnings per share (EPS) of 404.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does COSMOS Pharmaceutical pay a dividend?
COSMOS Pharmaceutical offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is COSMOS Pharmaceutical financially healthy?
COSMOS Pharmaceutical carries a debt-to-equity ratio of 0.28x and a current ratio of 0.77x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is COSMOS Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For COSMOS Pharmaceutical (3349) the key facts are: market cap ¥489.9B, P/E 15.3x, revenue ¥1.10T, 52-week range 5615-10045. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track COSMOS Pharmaceutical's full fundamentals live
Get COSMOS Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.